Majority of US patients' groups siding with Big Pharma against Medicare Part B pricing reforms receive industry funding; report

The overwhelming majority of US patients’ groups opposing a Medicare Part B proposal to reduce drug expenditures got funding from the pharmaceutical industry, according to a new Public Citizen report.

The US consumer advocacy’s report, “Patients’ Groups and Big Pharma,” examined industry funding for 147 patients’ groups publicly opposing the Medicare Part B proposal, documenting disclosures of funding and sponsorships from the drug and medical device industry to 110 of those groups (75% of the total).